Trial Profile
A Prospective Observational, multicenter, cohort Study of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PROSIT-BIO
- 13 Mar 2018 New trial record